Tech Company Financing Transactions
Debut Biotechnology Funding Round
Debut Biotechnology, operating out of San Diego, raised $34 million from L'Oreal BOLD Ventures, ACVC Partners and Cavallo Ventures.
Transaction Overview
Company Name
Announced On
6/1/2023
Transaction Type
Venture Equity
Amount
$34,000,000
Round
Series B
Investors
Proceeds Purpose
This Fund, will enable Debut to bring novel bioactive cosmetic ingredients and products to consumers worldwide.
Company Information
Company Status
Private & Independent
Industry
Manufacturing
Mailing Address
6330 Nancy Ridge Dr. 106
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Not Recorded
Overview
Debut Biotechnology is commercializing cell-free biomanufacturing solutions by creating advanced enzyme-based manufacturing processes for high-value molecules. Our platform combines immobilized enzymes with highly controlled and automated continuous manufacturing systems for the pharmaceutical and specialty chemical industries.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Britton
Browse more venture capital transactions:
Prev: 6/1/2023: Demox Labs venture capital transaction
Next: 6/1/2023: Riverse venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs